Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroimmunol ; 227(1-2): 185-9, 2010 Oct 08.
Article in English | MEDLINE | ID: mdl-20728948

ABSTRACT

We explore the safety, and therapeutic benefit of intrathecal injection of ex-vivo expanded autologous bone marrow derived mesenchymal stem cells (BM-MSCs) in 10 patients with advanced multiple sclerosis (MS). Patients were assessed at 3, 6 and 12 months. Assessment at 3-6 months revealed Expanded Disability Scale Score (EDSS) improvement in 5/7, stabilization in 1/7, and worsening in 1/7 patients. MRI at 3 months revealed new or enlarging lesions in 5/7 and Gadolinium (Gd+) enhancing lesions in 3/7 patients. Vision and low contrast sensitivity testing at 3 months showed improvement in 5/6 and worsening in 1/6 patients. Early results show hints of clinical but not radiological efficacy and evidence of safety with no serious adverse events.


Subject(s)
Bone Marrow Transplantation/immunology , Mesenchymal Stem Cell Transplantation/methods , Multiple Sclerosis/pathology , Multiple Sclerosis/surgery , Adult , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/pathology , Cells, Cultured , Feasibility Studies , Female , Follow-Up Studies , Humans , Injections, Spinal , Male , Mesenchymal Stem Cell Transplantation/adverse effects , Middle Aged , Pilot Projects , Transplantation, Autologous , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...